Monensin suppresses cell proliferation and invasion in ovarian cancer by enhancing MEK1 SUMOylation

SHUJUAN YAO1,2, WEN WANG3, BIN ZHOU4, XIUJUAN CUI3, HUI YANG3 and SHIQIAN ZHANG1

1Department of Obstetrics and Gynecology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012; 2Department of Obstetrics and Gynecology, Affiliated Hospital of Shandong University of TCM, Jinan, Shandong 250014; 3Department of Obstetrics and Gynecology, Jining Medical University Affiliated Tengzhou Central People's Hospital, Tengzhou, Shandong 277599; 4Department of Obstetrics and Gynecology, Tai'an City Central Hospital, Tai'an, Shandong 271000, P.R. China

Received October 18, 2020; Accepted June 30, 2021

DOI: 10.3892/etm.2021.10826

Abstract. Ovarian cancer is the most lethal gynecologic malignancy, and is usually diagnosed at an advanced stage. Most patients relapse within 12-24 months and die from progressive chemotherapy-resistant diseases. Significant progress has been made in developing new targeted therapies for human cancer, including ovarian cancer. However, an effective alternative to drug development is to repurpose drugs. The present study investigated the possibility of reusing the antibiotic monensin as an anti-ovarian cancer drug. After applying a series of titrated monensin on a panel of ovarian cancer cell lines, the growth, migration and invasion of cells were explored. Multiple signaling molecules associated with epithelial-to-mesenchymal transition were also regulated by monensin. The mitogen-activated protein kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway was further found to be the key regulator affected by monensin. Additionally, monensin enhanced the MEK1 SUMOylation in vitro and in vivo, and the SUMOylation degree depended on time and dose. Xenograft studies verified that monensin effectively inhibited xenograft tumor growth by increasing the SUMOylation of MEK1. The aforementioned results suggested that monensin is a good candidate for anti-ovarian cancer by enhancing MEK1 SUMOylation and inhibiting the MEK-ERK pathway.

Correspondence to: Professor Shiqian Zhang, Department of Obstetrics and Gynecology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, 107 West Wenhua Road, Jinan, Shandong 250012, P.R. China
E-mail: zhangshiqian370112@126.com

Abbreviations: EMT, epithelial-to-mesenchymal transition; MEK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase

Key words: monensin, ovarian cancer, SUMOylation, MEK1

Introduction

Ovarian cancer is the most common lethal gynecological malignancy. More than two-thirds of patients are diagnosed at a late stage [Federation Internationale of Gynecologie and Obstetrique (FIGO), stages III or IV], and the five-year survival rate is <30% (1,2). Carcinoma diagnosed in situ could elevate the five-year survival rate to 92% (1,3), but a diverse group of tumors in epithelial ovarian cancer impedes the early detection and new therapeutic approaches. Accumulating evidence has indicated that epithelial-to-mesenchymal transition (EMT) plays a crucial role in the development of ovarian cancer, which is a major driver of mortality in patients with cancer, whereas EMT is upregulated by the mitogen-activated protein kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway (4,5). The ERK/MAPK cascade mediates mitogenic signaling and is essential for the control of cell fate, differentiation and proliferation, which is frequently hyperactivated in human cancer (6).

MEK/ERK pathways are regulated by various mechanisms (6,7). Protein phosphorylation is one of the most important formats: Activated Raf phosphorylation and activates MEK1 and MEK2, which then phosphorylates ERK1 and ERK2, respectively (8,9). The protein Small ubiquitin-like modifier (SUMO) is an important pathway for modulating cellular function (10). SUMOs are small ubiquitin-like modifiers containing 92-97-amino-acid polypeptides (11). Similar to phosphorylation, SUMOylation is a reversible and dynamic process involving the activation of enzyme and cysteine proteases, which in turn modulate the function, subcellular localization, complex formation and/or stability of substrate proteins.

Monensin (Rumensin™) is a polyether ionophore antibiotic secreted by the bacterium Streptomyces cinnamomensis (12,13). Previous studies have demonstrated that monensin exerts cytotoxic effects against several types of cancer cells (14-16), but the underlying mechanism has not yet been thoroughly explored.

In the present study, the anticancer activity of monensin against human ovarian cancer cells was investigated by using a series of human ovarian cancer lines. Further studies indicated
that monensin effectively abrogated MEK SUMOylation, resulting in the enhanced activation of the ERK pathway, whereas SUMOylation faded with medium change and monensin withdrawal. Overall, the present study results revealed a previously unknown mechanism of monensin against ovarian carcogenesis.

**Materials and methods**

**Cell culture.** Human ovarian cancer cell lines SK-OV-3, A2780, OVCAR3 and CAOV-3 were purchased from the American Type Culture Collection. The aforementioned cells were maintained in complete Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (FBS; Invitrogen; Thermo Fisher Scientific, Inc.) at 37°C in 5% CO₂.

**Chemicals.** Monensin (cat. no. S2324; Selleck Chemicals) were added to the cells following the indicated concentration. Monensin was dissolved in ethanol at 50 mM for storage in -80°C. When used, monensin was diluted 1:1,000 with DMEM, and added to cellular medium based on the total volume for working solutions, such as 0.2, 1 and 5 µM.

**Cell proliferation assay.** Cell proliferation in response to monensin in vitro was assessed by Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies, Inc.) assay according to the manufacturer's instructions. Ovarian cancer cells were cultured at a density of 5x10⁴ per well in FBS 10% (v/v) DMEM medium on 96-well plate at 37°C. After 24 h of incubation, the culture medium were treated with monensin for 24, 48 and 72 h respectively. Then, 10 µl CCK-8 reagent was added to each well followed by incubation at 37°C for 2 h. Absorbance was measured using a microplate reader (Molecular Devices, LLC) at 450 nm with a reference wavelength of 650 nm.

The CellTiter-Glo (CTG) Luminescent Cell Viability assay is a homogenous method of determining the number of viable cells in culture based on the quantitation of the ATP present, which signals the presence of metabolically active cells. The cells were cultured in 96-well plates and treated with monensin for 24, 48 and 72 h respectively. Before luminescence recording, 100 µl CTG reagent (Promega Corporation) was added to each well, and the contents were mixed for 2 min on a shaker to induce cell lysis. The plate was equilibrated to room temperature for 10 min, and the luminescence signal was recorded on an Ascent luminometer (Thermo Labsystems) according to the manufacturer's protocols. Data was recorded as the mean ± SD of three independent experiments.

**Cell wounding assay.** Exponentially growing ovarian cancer cells were seeded onto 6-well plates until 80% confluence was reached. A sterile tip was used to create a wound in a cell monolayer, which was then washed 3 times to remove non-adherent cells. Fresh medium with 10% FBS was then added to the cultures. Images were captured at 0, 24, and 48 h after scratching. Photoshop software (Adobe Photoshop CS6; Adobe Systems, Inc.) was used to measure the distance of the wound at each time point, and the wound healing rate was calculated as follows: Wound healing rate = (control group wound width - sample group wound width)/control group wound width x100%. Data was recorded as the mean ± SD of three independent experiments.

**Transwell and invasion assay.** Ovarian cancer cells were seeded onto the upper chamber with 80% confluence. Ovarian cancer cells were starved by incubating in serum-free medium for 24 h. Culture inserts of 8-µm pore size (Transwell, Costar; Corning, Inc.) were placed onto the wells of 24-well culture plates. The solution containing the test agent was placed below the permeable cell membrane, and 1x10⁵ cells were seeded onto the upper chamber. After 48 h of incubation at 37°C with 5% CO₂, the number of cells that had migrated through the pores were fixed with 4% paraformaldehyde at room temperature (RT) for 20 min, and stained with 0.5% crystal violet for 3 min at RT. The photos were imaged at x200 magnification under an inverted microscope (NIB-100F; Ningbo Yongxin Optics Co., Ltd.), and the number of invading cells was determined with ImageJ software 1.42 (National Institutes of Health).

For the cell migration assay, culture inserts of 8-µm pore size were coated with Matrigel (BD Biosciences; 100 µg/well) and placed onto the wells of 24-well culture plates. The subsequent steps were as aforementioned for the Transwell experiments. The number of migrated cells were imaged at x200 magnification under an inverted microscope (NIB-100F; Ningbo Yongxin Optics Co., Ltd.), and determined with ImageJ, and data was recorded as the mean ± SD of three independent experiments.

**Cell cycle analysis.** Exponentially growing ovarian cancer cells were seeded onto 6-well plates at a density of 5x10⁴ and allowed to culture for 24 h. The cells were later treated with various concentrations of monensin and stored for 48 h. After treatment, cells were harvested with trypsin, pelleted by centrifugation, and washed with PBS. The cells were resuspended in PBS and fixed in ice-cold 70% ethanol for 24 h at 4°C. After fixation, cells were centrifuged at 2,500 x g for 30 sec and washed twice with PBS at RT, and then 1 ml propidium iodide master mix solution (40 µl PI, 10 µl RNAse and 950 µl PBS) were added and incubated at 37°C for 30 min in darkness. The cell cycle arrest was analyzed by flow cytometry (Accuri C6, BD Biosciences). The percentage of cell populations in the G₁, S, and G₂/M phases was analyzed with Modfit LT 4.0 software (Verity Software House, Inc.). Measurements were repeated independently three times.

**Western blot analysis.** Ovarian cancer cells were lysed in RIPA buffer plus protease inhibitors (XinShengyuan). Protein concentrations of the cell lysates were determined by bicinchoninic acid kit (BCA; cat. no. P0012, Beyotime Institute of Biotechnology). The lysates were loaded 20-60 µg per lane, separated on 10% SDS-PAGE, then the samples were transferred onto a polyvinylidene fluoride membrane (cat. no. ISEQ00010; EMD Millipore), and blocked by incubation with 5% fat-free milk in TBST buffer (150 mM NaCl, 50 mM Tris-HCl and 0.5% Tween-20, pH 7.6) at RT for 1 h. The membranes were incubated with primary antibodies at room temperature for 1 h and then with horseradish peroxide (HRP) conjugated secondary antibodies (OriGene Technologies, Inc.), such as HRP conjugated goat anti-mouse IgG (cat. no. ZB-2305) and HRP conjugated goat anti-rabbit IgG (cat.
Approximately nude mice (5-6 week old; 16-18 g; female) were purchased. Approximately 20 µl drug preservation solution or 100% ethanol was added to prepare 12 mg/ml and 24 mg/ml drug storage solution; 100% ethanol was used as the control group. Before injection, it is necessary to mix the drug solutions before injection. The weight and palpable tumors were typically observed within 2 weeks after injection of cells, and tumor sizes were measured with a caliper 15 days after cell injection. Tumor volumes were calculated using the following formula: volume (mm³) = length x width²/2. The maximum diameter of a single subcutaneous tumor was <1 cm. All mice were sacrificed at 3 weeks by inhalation of CO₂ gas, with a flow rate 20% replacement of home cage volume/min. Death was verified by cessation of the heartbeat and lack of movement, and the CO₂ flow was maintained for at least 3 min after cardiac arrest. The tumors were retrieved for western blotting assay. Multiple tumors were not observed in any of the mice.

**Statistical analysis.** Data are expressed as the mean ± standard deviation and analysis performed using SPSS v19.0 (IBM Corp.). All assays were performed in triplicate and/or repeated three times. Statistical significances were determined by one-way ANOVA test and Tukey’s test. P<0.05 was considered to indicate a statistically significant difference.

**Results.**

Monensin inhibits the cell proliferation of human ovarian cancer cells. The inhibitory effects of antibiotic monensin on human ovarian cancer were initially tested on SK-OV-3 cells by CCK-8 assay. SK-OV-3 is commonly used as a model for ovarian cancer to detect the effects and potency of various chemicals. Sub-confluent SK-OV-3 cells were treated with 0, 0.2, 1 and 5 µM monensin for 24, 48 or 72 h, respectively, and then detected. CCK-8 cell viability assay suggested that cell proliferation was suppressed with increased monensin concentration and incubation duration. As low as 0.2 µM monensin showed an inhibitory effect, whereas completely inhibited cell proliferation was observed in the first 24 h as high as 5 µM monensin (Fig. 1A). CTG lucinescent cell viability assay determined metabolically active cells according to the quantification of the ATP present. Based on the luminescence signal, CTG assay results indicated a similar inhibitory effect of monensin on cell proliferation with CCK-8 assay (Fig. 1B).

In order to validate the inhibitory effects of monensin on the proliferation of ovarian cancer cell SK-OV-3, monensin was applied on other ovarian cancer cell lines including A2780, OVCA3 and CAOV-3. Cell viability was detected by CCK-8 and CTG assays. When increased concentration of monensin (0.2, 1, and 5 µM) were added to the culture, all ovarian cancer cells showed similar results at 48 h post-treatment; their proliferative abilities were all effectively restrained by monensin (Fig. 1C and D).

Meanwhile, cell cycle distribution was analyzed by flow cytometry to detect the effect of monensin. The SK-OV-3 cells at the G2/M phase was significantly decreased from 19.17 to 12.82% when treated with 5 µM monensin (Fig. 1A and F). The A2780 cells showed similar results, and the ratio of G2/M phase was decreased from 19.64 to 13.37% when 5 µM

**Xenograft tumors of human ovarian cancer cells.** The use and care of animals were approved by ‘Animal Ethics Committee of Affiliated Hospital of Shandong University of Traditional Chinese Medicine’ (permit no. 2018-010). All experimental procedures were carried out in accordance with the approved guidelines, and every effort was made to minimize the suffering of animals. Animals were kept in a specific pathogen-free environment, in positive pressure rooms with modified Eagle’s medium supplemented with 10% FBS at a temperature of 23±2˚C, a controlled light and dark cycle (12 h: 12 h), ad libitum food and ultra-filtered water, 50-55% humidity, ventilated caging systems and standardized environmental enrichment.

Human ovarian cells SK-OV-3 were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% FBS at 37°C with 5% CO₂. Specific pathogen-free female athymic nude mice (5-6 week old; 16-18 g; female) were purchased from Beijing HFK Boscience and were housed three per cage under specific pathogen-free conditions. Approximately 5x10⁶ cells were injected subcutaneously into the right flank of 5- to 6-week-old female athymic nude mice. The mice were divided into three groups (n=3 per group) and treated with various doses of monensin (0, 8 or 16 mg/kg body weight) at 3, 6, 9 and 12 days. Monensin was dissolved in 100% ethanol to prepare 12 mg/ml and 24 mg/ml drug storage solution; 100% ethanol was used as the control group. Before injection, 20 µl drug preservation solution or 100% ethanol was added to ~180 µl sterile PBS (plus 1% penicillin and streptomycin) and diluted into 200 µl working solution. Each dose was calculated according to the body weight of nude mice as follows: 8 mg/kg in the low-concentration group, 16 mg/kg in the high-concentration group, and 0 mg/kg in the control group (containing only 10% ethanol). It is necessary to mix the drug solutions before injection. The weight and palpable tumors were typically observed within 2 weeks after injection of cells, and tumor sizes were measured with a caliper 15 days after cell injection. Tumor volumes were calculated using the following formula: volume (mm³) = length x width²/2.
monensin was applied (Fig. 1G and H). The aforementioned results indicated that monensin inhibited ovarian cancer cell proliferation by blocking DNA replication.

*Monensin inhibits cell invasion and malignant transformation of human ovarian cancer cells.* Migration, invasion and transformation are key procedures and important features of malignant cancer. In the Transwell assay, cells treated with 0.2 µM monensin had similar colon number and passing-through-membrane percentage compared with the control group. However, the number of Transwell cells dropped to about 100, whereas the percentage was decreased to 30%
when 1 µM monensin was applied to cells. The number and percentage dropped dramatically to 50 and 10% when more monensin was added (5 µM) (Fig. 2A and B). Overall, a series of concentrations (0, 0.2, 1 and 5 µM) of monensin was applied in the Transwell assay, and the ability of malignant transformation of human ovarian cancer showed significant impairment and dose-dependent effect (Fig. 2C and D). Moreover, when 1 µM monensin was applied to cells for 48 h, the gap closure
YAO et al.: MONENSIN ENHANCES MEK1 SUMOylation

showed time-dependent decrease (Fig. 2E), and the wound healing rate of cells treated with 1 µM monensin was significantly decreased compared with the control group (Fig. 2F).

Monensin restrains the EMT-associated signaling pathway. Next, the EMT-associated signaling molecules were investigated in ovarian cancer cell lines. E-cadherin and claudin are EMT promoters, and vimentin enables dynamic cell elongation. In SK-OV-3 cells treated with monensin, the expression level of E-cadherin and claudin increased to 30% of the control, whereas the expression level of vimentin decreased to half of the control since monensin accumulated to 5 µM. The aforementioned findings showed a concentration-dependent response (Fig. 3A and B).

Moreover, E-cadherin and claudin can be activated by the RAS-RAF-MEK-ERK cascade, and the potential attenuation of this pathway by monensin was evaluated by western blotting. The results revealed a specific decrease in the levels of phosphorylated ERK and MEK protein in SK-OV-3 cells treated with monensin compared with the control cells. The total MEK and ERK levels were also decreased when treated with monensin. The regulation of the MEK-ERK pathway was highly associated with cell proliferation (18), which explained the monensin-induced growth inhibition. The specific inhibitor of ERK, SCH772984, served as a positive control, which showed similar results (Fig. 3C and D). Recovery assay further showed that monensin inhibited ERK phosphorylation. Monensin was removed after 24 h of incubation, and the

Figure 3. Monensin inhibits the MEK/ERK pathway and epithelial-mesenchymal transition. (A) p-MEK, ERK, total MEK, ERK, E-cadherin, vimentin and claudin expression levels were measured by western blotting at indicated concentrations of monensin. The densitometry analysis is shown in (B). (C) The inhibitor of ERK, SCH772984, was used to detect the E-cadherin, vimentin and claudin expression levels by western blotting, and gray scale scanning analysis is shown in (D). (E) Monensin was removed after incubation for 24 h, and the p-ERK level in cells 12 h after monensin removal was detected by western blotting. The densitometry analysis is shown in (F). All assay conditions were conducted in triplicate, and the representative results are presented. *P<0.01 vs. control. p-, phosphorylated.
phospho-ERK level in cells after 12 h of monensin removal became much higher compared with that of cells incubated with monensin (Fig. 3E and F).

**Monensin enhances the SUMOylation of MEK1.** Protein SUMOylation is associated with various cellular functions, such as cell proliferation and invasion. MEK1 SUMOylation is an important way to regulate the MEK-ERK pathway. To determine whether MEK underwent SUMOylation in ovarian cancer cell line, MEK1 was expressed together with SUMO1 in HEK293 cells. MEK1 was immunoprecipitated with anti-MEK1 monoclonal antibodies and protein G, separated by SDS-PAGE, and detected with anti-SUMO monoclonal antibodies (Fig. 4A and B). The results indicated that monensin enhanced the SUMOylation modification of MEK1 with increased drug concentration and growth of drug action time (Fig. 4C and D).

To identify the function of monensin on MEK SUMOylation and MEK-ERK phosphorylation cascade, cells transfected with MEK1 and SUMO1 were incubated with the drug for 24 h and the fresh medium was changed to a fresh one. At the time points of 2, 4 and 6 h, SUMOylated MEK1,
phosphorylated MEK1 and total MEK1 were detected by IP analysis. The results indicated that SUMO modification was detached upon drug removal, thereby confirming the effects of monensin on MEK1 SUMOylation. Moreover, with the withdrawal of SUMO modification, the phosphorylation of MEK1 was increased (Fig. 4E and F), whereas cell viability and proliferation were recovered (Fig. 4G). It can be concluded that SUMOylation significantly attenuated MEK1 activity in ovarian cancer cells by downregulating ERK signaling, and the process was reversible.

Monensin suppresses xenograft tumor growth and enhanced MEK1 SUMOylation in vivo. Monensin exerted significant effects on the proliferation, migration and invasion of ovarian cancer cells in vitro. Accordingly, the anticancer effects of monensin on the establishment and progression of ovarian cancer was explored in vivo. SK-OV-3 ovarian cancer cells were injected subcutaneously into the flanks of nude mice. At 3 days post-injection, the animals were treated with three doses (0, 8 and 16 mg/kg) of monensin. The tumor masses were retrieved on day 20, and the control group had significantly larger individual tumors and higher average tumor volume compared with monensin-treated groups (Fig. 5A and B). Besides, MEK1 SUMOylation was strengthened with increased monensin dosage in vivo, consistent with the data in vitro (Figs. 5C and 4D). Together, monensin effectively inhibited tumor growth in ovarian cancer xenograft model by MEK1 SUMOylation reinforcement.

Discussion

Ovarian cancer is the most lethal tumor type among malignancies in females with high incidence and mortality rate. Most patients are diagnosed at a late stage (III and IV) and undergo different responses to chemotherapy (1). A gap currently exists between efficient treatment and clinical agents for ovarian cancer. Thus, the demand for developing effective and novel therapies to ovarian cancer is urgent.

Monensin has been approved by the Food and Drug Administration as a safety medicine in veterinary medicine. Several studies have also indicated its inhibitory effects on different types of cancer, such as prostate, melanoma and acute myeloid leukemia (15,17,18). Monensin can work by freely passing through the lipid bilayer of the cytoplasmic membrane along with passive diffusion (19), but the mechanism on anticancer activity is unclear. The present study explored the possible mechanism underlying the effects of monensin on ovarian cancer.

Firstly, monensin was found to suppress the proliferation of different type of ovarian cells to minor varying degrees. Cell-cycle distribution analysis verified the inhibitory effect of monensin at the G1/S phase. Meanwhile, monensin was
detected to inhibit the invasion and migration of ovarian cells, as well as to be highly associated with the expression of EMT-associated signaling molecules (such as E-cadherin, claudin and vimentin) and the central kinase of MEK and ERK (20,21). E-cadherin is required for progression through EMT, which contributes to the loss of adherent junctions (22), whereas vimentin is an intermediate filament composition that changes cytoskeletal and polarity complex proteins and in turn contributes to EMT (23). Claudin-linked protein complexes exist between adjacent epithelial or endothelial cells, and the dissolution of tight junctions during EMT is accompanied by decreased Claudin (24). Overall, E-cadherin, claudin and vimentin were all associated with accelerated tumor growth, invasion and poor prognosis.

Furthermore, it was found that monensin intensified the SUMO1 modification of MEK1, which attenuated MEK1 activity by inhibiting MEK1 activation and negatively regulated the ERK pathway, finally suppressing cellular overgrowth. The aforementioned finding suggested that SUMO modification was a reversible and highly dynamic process, which changed with drug concentration and duration time. Results of in vivo xenograft studies further confirmed that monensin effectively inhibited xenograft tumor growth by inhibiting cell proliferation and enhancing the SUMOylation of MEK. SUMOylation is an important modulation of protein function and cell fate, and is highly responsive to various stimuli and cellular micro-environment (25).

Together, the results of the present study strongly suggested that monensin functioned as an anti-ovarian cancer agent and provided first evidence that the SUMO1 modification of MEK played crucial roles in ovarian carcinogenesis. The present study can guide future studies on the anticancer efficacy of monensin in preclinical and clinical studies. In the present study, monensin was shown to inhibit the MEK-ERK pathway and EMT, through in vitro and in vivo experiments, by enhancing MEK1 SUMOylation.

Acknowledgements

Not applicable.

Funding

This study was supported by Funds for Teachers’ research of Jining Medical University (grant no. JYFC2019FKJ136).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

SZ conceived and supervised the study; SY designed experiments and wrote the original manuscript; WW established the xenograft model; BZ and XC cultured cells and performed cell-based assay; HY analysed the data. SY and SZ confirm the authenticity of all the raw data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The use and care of animals were approved by ‘Animal Ethics Committee of Affiliated Hospital of Shandong University of Traditional Chinese Medicine’ (permit no. 2018-010).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65: 5-29, 2015.
2. Phillips-Chavez C, Watson M, Coward J and Schloss J: A systematic literature review assessing if genetic biomarkers are predictors for platinum-based chemotherapy response in ovarian cancer patients. Eur J Clin Pharmacol 76: 1059-1074, 2020.
3. Zhang R, Shi H, Ren F, Feng W, Cao Y, Li G, Liu Z, Ji P and Zhang M: MicroRNA-338-3p suppresses ovarian cancer cells growth and metastasis: Implication of Wnt/catenin beta and MEK/ERK signaling pathways. J Exp Clin Cancer Res 38: 494, 2019.
4. Wen J, Zhao Z, Huang L, Wang L, Miao Y and Wu J: IL-8 promotes cell migration through regulating EMT by activating the Wnt/β-catenin pathway in ovarian cancer. J Cell Mol Med 24: 1588-1598, 2020.
5. Fan T, Wang W, Ip PP, Zhou S, Wong AS, Wang X and Yang M: Single-cell EMT-related transcriptional analysis revealed intra-cluster heterogeneity of tumor cell clusters in epithelial ovarian cancer ascites. Oncogene 39: 4227-4240, 2020.
6. Wang S, Wang C, Li X, Hu Y, Guo R, Guo Q, Nie X, Liu J, Zhu L and Lin B: Down-regulation of TRIB3 inhibits the progression of ovarian cancer via MEK/ERK signaling pathway. Cancer Cell Int 20: 418, 2020.
7. Liu J, Hu HB, Liu YM, Li FX, Zhang LP and Liao ZM: LncRNA HOTTIP promotes the proliferation and invasion of ovarian cancer cells by activating the MEK/ERK pathway. Mol Med Rep 22: 3667-3676, 2020.
8. Wu PK, Becker A and Park JI: Growth inhibitory signaling of the Raf/MEK/ERK pathway. Int J Mol Sci 21: 21, 2020.
9. Parker MI, Nikonova AS, Sun D and Golemis EA: Proliferative signaling by ERBB proteins and RAF/MEK/ERK effectors in polycystic kidney disease. Cell Signal 67: 109497, 2020.
10. Nayak A and Amrute-Nayak M: SUMO system - a key regulator in sarcomere organization. FEBS J 287: 2176-2190, 2020.
11. Varejão N, Lascorz J, Li Y and Reverter D: Molecular mechanisms in SUMO conjugation. Biochem Soc Trans 48: 123-135, 2020.
12. Wan W, Zhang X, Huang C, Chen L, Yang X, Bao K and Peng T: Monensin inhibits glioblastoma angiogenesis via targeting multiple growth factor receptor signaling. Biochem Biophys Res Commun 530: 479-484, 2020.
13. Gu J, Huang L and Zhang Y: Monensin inhibits proliferation, migration, and promotes apoptosis of breast cancer cells via downregulating UBA2. Drug Dev Res 81: 745-753, 2020.
14. Dayekh K, Johnson-Obaseki S, Corsten M, Villeneuve PJ, Sekhon HS, Weberpals JI and Dimitroulakos J: Monensin inhibits epidermal growth factor receptor trafficking and activation: Synergistic cytotoxicity in combination with EGFR inhibitors. Mol Carcinogen 13: 2559-2571, 2014.
15. Markowska A, Kayssiewicz J, Markowska J and Huczynski A: Doxycycline, salinomycin, monensin and ivermectin repositioned as cancer drugs. Bioorg Med Chem Lett 29: 1549-1554, 2019.
16. Rajendran V, Ilimathi HS, Dutt S, Lakshminarayana TS and Ghosh PC: Chemotherapeutic potential of monensin as an antimicrobial agent. Curr Top Med Chem 18: 1976-1986, 2018.
17. Xin H, Li J, Zhang H, Li Y, Zeng S, Wang Z, Zhang Z and Deng F: Monensin may inhibit melanoma by regulating the selection between differentiation and stemness of melanoma stem cells. PeerJ 7: e7354, 2019.
18. Yusenko MV, Trentmann A, Andersson MK, Ghani LA, Jakobs A, Arteaga Paz MF, Mikesch JH, Peter von Kries J, Stenman G and Klempnauer KH: Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells. Cancer Lett 479: 61-70, 2020.

19. Vanneste M, Huang Q, Li M, Moose D, Zhao L, Stamnes MA, Schultz M, Wu M and Henry MD: High content screening identifies monensin as an EMT-selective cytotoxic compound. Sci Rep 9: 1200, 2019.

20. Hu M, Zhang Y, Li X, Cui P, Li J, Brännström M, Shao LR and Billig H: Alterations of endometrial epithelial-mesenchymal transition and MAPK signalling components in women with PCOS are partially modulated by metformin in vitro. Mol Hum Reprod 26: 312-326, 2020.

21. Xin L, Zhao R, Lei J, Song J, Yu L, Gao R, Ha C, Ren Y, Liu X, Liu Y, et al: SND1 acts upstream of SLUG to regulate the epithelial-mesenchymal transition (EMT) in SKOV3 cells. FASEB J 33: 3795-3806, 2019.

22. Sommariva M and Gagliano N: E-cadherin in pancreatic ductal adenocarcinoma: A multifaceted actor during EMT. Cells 9: 9, 2020.

23. Avtanski D, Garcia A, Caraballo B, Thangeswaran P, Marin S, Bianco J, Lavi A and Poretsky L: Resistin induces breast cancer cells epithelial to mesenchymal transition (EMT) and stemness through both adenylyl cyclase-associated protein 1 (CAP1)-dependent and CAP1-independent mechanisms. Cytokine 120: 155-164, 2019.

24. Wang K, Li T, Xu C, Ding Y, Li W and Ding L: Claudin-7 down-regulation induces metastasis and invasion in colorectal cancer via the promotion of epithelial-mesenchymal transition. Biochem Biophys Res Commun 508: 797-804, 2019.

25. Jansen NS and Vertegaal ACO: A chain of events: Regulating target proteins by SUMO polymers. Trends Biochem Sci 46: 113-123, 2021.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.